New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancerSALT LAKE CITY, June 11, 2024…
Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT PlatformPatent Application Also…
MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader…
STONY BROOK, NY / ACCESSWIRE / May 28, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and CollaboratorsSALT…
PASADENA, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GeneType”), a global leader…
STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…
STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…
STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…
GREENVILLE, SC / ACCESSWIRE / May 2, 2024 / Rymedi and Precision Genetics, two leading pioneers in healthcare technology solutions,…